D86.86
BillableSarcoid arthropathy
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is D86.86 an HCC code?
Yes. D86.86 maps to Rheumatoid Arthritis and Inflammatory Connective Tissue Disease under the CMS-HCC V28 risk adjustment model.
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for D86.86
For D86.86 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D86.86 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
D86.86 is the ICD-10-CM diagnosis code for sarcoid arthropathy. Joint inflammation and arthritis caused by sarcoidosis, typically affecting the ankles, knees, and other joints, causing pain and swelling. D86.86 sits in the ICD-10-CM chapter for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89), within the section covering certain disorders involving the immune mechanism (d80-d89).
Under the CMS-HCC V28 risk adjustment model, D86.86 maps to Rheumatoid Arthritis and Inflammatory Connective Tissue Disease (HCC 93) with a community, non-dual, aged base RAF weight of 0.175. D86.86 was not retained as a payment HCC under the older V24 model, so V28 introduced or recategorized it during the 2024–2026 phase-in. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Specify which joints are involved when documentation permits. Because D86.86 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for D86.86 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Specify which joints are involved when documentation permits
- •Do not confuse with rheumatoid arthritis; confirm sarcoidosis as the primary cause
Clinical Significance
Sarcoid arthropathy is a musculoskeletal manifestation of sarcoidosis that can present as acute or chronic joint inflammation, affecting approximately 25-40% of sarcoidosis patients. Acute sarcoid arthritis often accompanies Lofgren syndrome (bilateral hilar lymphadenopathy, erythema nodosum, and polyarthralgia), while chronic sarcoid arthropathy can cause persistent joint damage. The condition requires distinction from other inflammatory arthropathies for appropriate management.
Documentation Requirements
- ✓The provider must document sarcoidosis as the confirmed etiology of the arthropathy, specifying affected joints and whether the presentation is acute or chronic.
- ✓Documentation should include supporting evidence such as elevated angiotensin-converting enzyme levels, imaging findings, and any biopsy results confirming non-caseating granulomas.
- ✓Current treatment and functional impact should be noted.